SCHEDULE 13D/A: Biodesix Insider Jack Schuler Boosts Stake to 24%

Sentiment:

Insider Ownership Update 27 January 2026 7:28 PM

Jack W. Schuler, an emeritus director of Biodesix Inc., increased his beneficial ownership in the company to 24.0% through recent open market purchases.

Better than expectedA significant insider, Jack W. Schuler, increased his stake in the company through open market purchases, signaling confidence in the company's future prospects.

Summary

Jack W. Schuler, an emeritus director of Biodesix Inc., increased his beneficial ownership in the company's common stock.
His aggregate beneficial ownership now stands at 2,333,945 shares, representing approximately 24.0% of the shares outstanding.
This includes 20,735 shares he has the right to acquire within 60 days (4,156 from options and 16,579 from vested RSUs).
The majority of his holdings are through the Jack W. Schuler Living Trust (1,563,210 shares, 16.1%) and the Jack W. Schuler 2025 GRAT (750,000 shares, 7.7%).
Between January 22 and January 26, 2026, Mr. Schuler, through the Trust, purchased a total of 182,465 shares in the open market.
These purchases were made at weighted average prices ranging from $10.9569 to $11.8084 per share, using his personal funds.

Sentiment

Score: 7

Explanation: The increased stake by a significant insider, particularly an emeritus director, suggests strong confidence in the company's valuation and future, which is generally a positive signal for investors.

Positives

A significant insider, Jack W. Schuler, increased his stake in Biodesix Inc. by purchasing 182,465 shares in the open market.
The increase in beneficial ownership to 24.0% demonstrates strong conviction from a key individual with deep knowledge of the company.
The purchases were made at prices ranging from $10.675 to $12.05, indicating a belief in the company's value at these levels.

Future Outlook

No specific forward-looking statements or guidance are provided in this filing, which focuses on changes in beneficial ownership.

Industry Context

This filing primarily details an insider's increased stake and does not provide broader industry context or analysis of trends or competitors.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Director	Jack W. Schuler	Jack W. Schuler (Emeritus Director)	2025-05-20	Transitioned to emeritus director role at the 2025 Annual Meeting of Stockholders.

Related Party Transactions

Jack W. Schuler, as the reporting person, made open market purchases through the Jack W. Schuler Living Trust, where he serves as sole trustee, and holds shares through the Jack W. Schuler 2025 GRAT, where he also serves as sole trustee. These transactions represent an increase in his indirect beneficial ownership.

Stakeholder Impact

Shareholders: The increased insider ownership by a prominent individual like Jack W. Schuler could be perceived positively, potentially boosting investor confidence and signaling a belief in the company's long-term value.
Management: Continued significant ownership by a former director may align interests with current management, though his role is now emeritus.

Key Dates

Date	Description
2020-11-09	Initial Schedule 13D filed with the U.S. Securities and Exchange Commission.
2022-01-28	Amendment to Schedule 13D filed.
2022-04-11	Amendment to Schedule 13D filed.
2022-11-23	Amendment to Schedule 13D filed.
2023-08-11	Amendment to Schedule 13D filed.
2024-04-09	Amendment to Schedule 13D filed.
2024-05-23	Amendment to Schedule 13D filed.
2025-05-20	Mr. Schuler transitioned to the role of emeritus director at the Issuer's Annual Meeting of Stockholders.
2025-09-03	Amendment to Schedule 13D filed.
2025-09-23	Amendment to Schedule 13D filed.
2026-01-22	Mr. Schuler, through the Trust, purchased 82,465 Shares in the open market.
2026-01-23	Mr. Schuler, through the Trust, purchased 80,000 Shares in the open market; Issuer provided 9,685,789 Shares outstanding.
2026-01-23	Date of event which requires filing of this statement.
2026-01-26	Mr. Schuler, through the Trust, purchased 20,000 Shares in the open market.
2026-01-27	Date of filing of this Amendment No. 10.

Recommendation

buy

The substantial increase in beneficial ownership by Jack W. Schuler, a long-standing insider and emeritus director, through open market purchases at current price levels, indicates strong conviction in Biodesix's future prospects and valuation. Such insider buying often precedes positive developments or reflects a belief that the stock is undervalued, making it a compelling 'buy' signal for seasoned investors.

Keywords

Biodesix Inc., BIOD, Jack W. Schuler, Schedule 13D, Insider Buying, Share Ownership, Common Stock, Investment, Biotech, Medical Diagnostics

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.